Sarepta Therapeutics (SRPT) EBITDA (2010 - 2026)

Sarepta Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at $358.4 million for Q1 2026.

• On a quarterly basis, EBITDA rose 219.32% year-over-year to $358.4 million in Q1 2026; TTM through Mar 2026 was -$41.0 million, a 65.05% increase from a year earlier, with the FY2025 full-year figure at -$699.8 million, down 420.88% from the prior year.
• EBITDA improved to $358.4 million in Q1 2026 per SRPT's latest filing, from -$411.6 million in the prior quarter.
• Across five years, EBITDA topped out at $358.4 million in Q1 2026 and bottomed at -$411.6 million in Q4 2025.
• The 5-year median for EBITDA is -$86.9 million (2022), against an average of -$54.5 million.
• Biggest YoY gain for EBITDA was 16587.45% in 2025; the steepest drop was 960.58% in 2025.
• Year by year, EBITDA stood at -$106.8 million in 2022, then soared by 123.05% to $24.6 million in 2023, then jumped by 556.57% to $161.7 million in 2024, then plunged by 354.56% to -$411.6 million in 2025, then soared by 187.09% to $358.4 million in 2026.
• Per Business Quant, the three latest SRPT EBITDA figures stand at $358.4 million (Q1 2026), -$411.6 million (Q4 2025), and -$103.4 million (Q3 2025).